ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Albumin-Bound Paclitaxel

Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.

Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.

Drug pageAlbumin-Bound Paclitaxel: every studyMany companies study it; this page follows only the 51 they lead. All 527 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 28, 201451 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only380 open or runningphase 4since May 28, 2014Sep 30, 2002none ahead
CSPC Pharmaceutical Groupits history only31 open or runningphase 3since Aug 15, 2017Aug 15, 2017none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Mar 24, 2016Mar 24, 2016none ahead
Astellas Pharmaits history only10 open or runningphase 1since Nov 6, 2009Nov 6, 2009none ahead
EBG MedAustronits history only11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
Lee's Pharmaceuticalits history only10 open or runningphase 1since Sep 8, 2020Sep 8, 2020none ahead
Novartisits history only10 open or runningphase 2since Jul 1, 2008Jul 1, 2008none ahead
NovoCure10 open or runningphase 2since Feb 29, 2024Feb 29, 2024none ahead
Otsukaits history only10 open or runningphase 2since Apr 16, 2008Apr 16, 2008none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 29, 2024First study: phase 2 study in Pancreatic NeoplasmsFirst studyNCT06390059 · 84 enrolled · Czechia, Germany, Spain and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study NovoCure leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more2CompletedNov 18, 202584

How it is read

Names in the registry

  • “ABI-007”, 15 entries
  • “nab-paclitaxel”, 13 entries
  • “Nab-paclitaxel”, 12 entries
  • “Nab-Paclitaxel”, 9 entries
  • “nab-Paclitaxel”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.